KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies
| Autor: | Hong Ding, Qing Chen, Wan Chun Yang, Li Xin Qiu, Jin Li, Ru Yan Liao, Fang Bing Du, Chen Mao |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.drug_class medicine.disease_cause Tyrosine-kinase inhibitor Proto-Oncogene Proteins p21(ras) Risk Factors Internal medicine Carcinoma Non-Small-Cell Lung Proto-Oncogene Proteins medicine Carcinoma Biomarkers Tumor Humans Epidermal growth factor receptor Lung cancer neoplasms Protein Kinase Inhibitors Genetic Association Studies biology business.industry Smoking Cancer medicine.disease Prognosis digestive system diseases respiratory tract diseases ErbB Receptors Drug Resistance Neoplasm Meta-analysis Immunology Mutation biology.protein ras Proteins Adenocarcinoma Female KRAS business |
| Zdroj: | Lung cancer (Amsterdam, Netherlands). 69(3) |
| ISSN: | 1872-8332 |
| Popis: | Epidemiologic studies have evaluated the association between KRAS mutations and resistance to the treatment of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). However, results were inconclusive. To derive a more precise estimation of the relationship, we performed this meta-analysis. Systematic computerized searches of the PubMed and Medline databases (up to Jun 30, 2009) were performed. A total of 22 studies were included in the final meta-analysis, consisting of 1470 NSCLC patients, of whom 231 had KRAS mutations (16%). Current or former smokers had a higher frequency of KRAS mutations than never smokers (25% versus 6%; OR=4.36; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect